Core Viewpoint - The National Healthcare Security Administration (NHSA) has been implementing the "Diagnosis-Related Group (DRG)" payment reform since 2019, which aims to enhance the efficiency of healthcare fund usage, ensure sustainable hospital development, and improve patient satisfaction. The 3.0 version of this payment model is expected to be released in 2026 [1][6]. Payment Reform Overview - The reform shifts the payment model from "fee-for-service" to "payment by diagnosis," meaning hospitals are compensated based on the diagnosis rather than the number of services provided [3][4]. - This change encourages hospitals to control costs and reduce unnecessary tests and treatments, as they receive a fixed payment for similar cases regardless of the actual expenses incurred [4][6]. Challenges and Issues - Some hospitals have reportedly imposed restrictions such as "no more than 15 days of hospitalization," leading to issues like premature discharges and inadequate treatment for complex cases [3][5]. - Experts highlight that the average length of stay is a key performance indicator for hospitals, which may lead to a focus on minimizing hospital stays rather than ensuring comprehensive patient care [5][6]. Future Adjustments and Goals - The upcoming 3.0 version of the DRG payment model is expected to introduce more refined grouping based on disease type, severity, and treatment methods, allowing for more precise payment standards [6][8]. - The NHSA aims to address the balance between efficient fund usage, sustainable hospital operations, and enhanced patient experiences through these adjustments [10]. Recommendations for Improvement - Experts suggest enhancing the service capabilities of primary care hospitals to manage minor illnesses locally while directing more severe cases to specialized hospitals [11]. - There is a call for improved reimbursement processes for patients seeking care across provinces and stricter regulation of hospital charging practices [11].

Core Insights - The article discusses the ongoing reform of the "Diagnosis-Related Group (DRG)" payment system in China's healthcare, which aims to improve the efficiency of medical insurance fund usage and enhance patient experience [1][4][13] Payment Reform Overview - The traditional payment method was based on "fee-for-service," which incentivized excessive medical practices. The DRG system groups similar cases and sets a unified payment standard based on historical data, promoting rational use of medical insurance funds [1][2] - The DRG payment reform has been implemented since 2019 and is set to evolve with the release of version 3.0 in 2026, aiming for better fund utilization, hospital sustainability, and improved patient satisfaction [1][13] Challenges and Solutions - Issues have arisen during the implementation, such as hospitals limiting patient stays to under 15 days and pushing patients out prematurely to control costs. This has led to concerns about the quality of care for complex cases [2][3] - Experts suggest that hospitals should collaborate with medical insurance departments to avoid cost-cutting measures that compromise patient care. A mechanism for special cases has been established in some regions to address these challenges [3][5] Case Study: Anyang City - Anyang City has implemented a unique approach where cases exceeding 60 days or requiring special treatment are settled separately, allowing hospitals to manage costs without compromising care [4][6] - In 2024, Anyang reported over 13,000 special cases with a total expenditure of 266 million yuan, demonstrating the effectiveness of this model in preventing premature discharges [6][7] Financial Outcomes - The reform has led to a surplus in the medical insurance fund, with Anyang's fund showing a balance after years of deficits. The total expenditure for hospitals has increased, and the average hospitalization cost has decreased significantly [7][9] - The average hospitalization cost in Anyang dropped from over 11,100 yuan in 2020 to 9,780 yuan in 2024, a reduction of 11.99% [9][10] Day Surgery Implementation - The introduction of "day surgery" has accelerated bed turnover and reduced costs, with nearly 60% of tertiary hospitals adopting this practice. Patients can now complete procedures within 24 hours, leading to lower expenses and resource optimization [10][12] - The average hospitalization duration has decreased, and personal out-of-pocket expenses have also declined, indicating a positive trend in patient care and cost management [12][13] Future Directions - The upcoming version 3.0 of the DRG payment system will focus on more refined classifications and regular updates to payment standards, ensuring that the system adapts to changes in medical practices and technologies [13][14] - Enhancing the service capacity of primary healthcare institutions and facilitating cross-province reimbursement for patients are essential steps for future improvements in the healthcare system [14]

Core Insights - The National Medical Insurance Administration (NMIA) has announced significant advancements in China's medical insurance system, including the establishment of a comprehensive medical insurance mechanism for outpatient medications for hypertension and diabetes, and the implementation of a payment reform by disease type by 2025 [1][2]. Group 1: Medical Insurance Developments - The total amount of personal account mutual aid in the employee medical insurance system has exceeded 100 billion yuan, benefiting over 780 million people in the past five years [1]. - A long-term mechanism to prevent poverty due to illness has been established, with medical assistance benefiting 1.189 billion people, and over 90% reimbursement for rural disadvantaged groups [1]. - The NMIA aims to achieve "no out-of-pocket" expenses for childbirth within the policy scope by 2026, expanding coverage for maternity insurance and long-term care insurance [3]. Group 2: Payment Reform and Management - By 2025, the NMIA will implement version 2.0 of the disease-based payment scheme, enhancing mechanisms for special cases, advance payments, and negotiation [2]. - All medical insurance regions will conduct real-time settlements, with monthly payment timelines reduced to within 20 working days after application, alleviating financial pressure on medical institutions [2]. - The NMIA plans to release version 3.0 of the disease-based payment grouping scheme in 2026, supporting the clinical use of new drugs and technologies [2]. Group 3: Fraud Prevention and Regulation - Over the past five years, approximately 120 billion yuan has been recovered from fraudulent medical insurance claims, with comprehensive coverage of inspections across all provinces [4][5]. - The NMIA has utilized big data models and intelligent regulatory systems to recover 9.5 billion yuan in fund losses, and has implemented drug traceability measures to combat illegal activities [4]. - In 2026, the NMIA will intensify inspection efforts, focusing on regions with high out-of-pocket rates and ensuring strict penalties for violations [5].

Policy Developments - The National Healthcare Security Administration (NHSA) has issued the "Interim Measures for the Management of Disease-Specific Payment" to promote a multi-faceted healthcare payment reform focused on disease-specific payments [1][2] - The framework consists of eight chapters and thirty-nine articles, emphasizing budget management, grouping scheme formulation, and core elements and supporting measures [2][3] - The introduction of this measure is expected to enhance the standardization of disease-specific payment systems and improve the efficiency of healthcare fund utilization [3] Drug and Medical Device Approvals - Kehua Bio's syphilis antibody quality control product has received a medical device registration certificate, which will enhance the company's product line [4] - Haikang Pharmaceutical's new indication application for HSK39297 tablets has been accepted, targeting age-related macular degeneration and generalized myasthenia gravis [5] Financial Reports - Leksin Medical reported a revenue of 521 million yuan for the first half of the year, a year-on-year increase of 4.57%, with a net profit of 42.29 million yuan, up 21.35% [6] - Gilead Sciences reported a revenue of 104 million yuan for the first half of the year, a significant increase of 111.4%, with a net loss of 87.95 million yuan, narrowing by 32.5% [7] Mergers and Acquisitions - Yunnan Baiyao plans to acquire 100% equity of Juyitang Pharmaceutical for 660 million yuan to enhance its business layout and expand its market presence [8] - Kangzhong Medical intends to invest 20 million yuan to acquire a 6.67% stake in Shanghai Renyan Information Technology to support its strategic transformation [9] Industry Events - Ji Xunming has been appointed as the president of the Chinese Academy of Medical Sciences and Peking Union Medical College [10] - The National Health Commission and the Ministry of Education are urging Beijing Union Medical College to rectify issues related to its "4+4" pilot program [11] Other Developments - Buchang Pharmaceutical's subsidiary plans to sign a technology transfer contract with Shandong University of Traditional Chinese Medicine for 15 million yuan [12] - Zhongke Investment plans to reduce its stake in Nanwei Medical by up to 2% due to funding needs [13] - Sichuan Medical Technology has received a notice from the Hangzhou Public Security Bureau regarding evidence collection related to a securities fraud investigation [14]

Policy Developments - The National Healthcare Security Administration (NHSA) has issued the "Interim Measures for the Management of Disease-Specific Payment in Medical Security" to promote a multi-faceted payment reform focused on disease-specific payments [2] - The measures consist of eight chapters and thirty-nine articles, emphasizing budget management, grouping scheme formulation, and core elements and supporting measures [2][3] - The new regulations aim to enhance the scientific level of medical insurance payments and standardize the payment process [2] Drug and Device Approvals - Kehua Bio's syphilis antibody quality control product has received a medical device registration certificate, which will enhance the company's product line [5] - Haikang's new indication application for HSK39297 tablets has been accepted, targeting age-related macular degeneration and myasthenia gravis, indicating potential for effective treatment [6] Financial Reports - Leksin Medical reported a revenue of 521 million yuan for the first half of the year, a year-on-year increase of 4.57%, with a net profit of 42.29 million yuan, up 21.35% [8] - Gilead Sciences reported a revenue of 104 million yuan for the first half of the year, a significant increase of 111.4%, with a net loss of 87.95 million yuan, narrowing by 32.5% [9] Capital Market Activities - Yunnan Baiyao plans to acquire 100% of the equity of Juyitang for 660 million yuan to enhance its business layout and expand its market presence [11] - Kangzhong Medical intends to invest 20 million yuan to acquire a 6.67% stake in Shanghai Renyan Information Technology to support its strategic transformation [12] Industry Events - Ji Xunming has been appointed as the president of the Chinese Academy of Medical Sciences and Peking Union Medical College, indicating a leadership change in a key medical institution [14] - The National Health Commission and the Ministry of Education are urging Beijing Union Medical College to rectify issues related to its "4+4" pilot program, focusing on stricter management and oversight [15] Public Sentiment Alerts - Zhongke Investment plans to reduce its stake in Nanwei Medical by up to 2%, indicating potential changes in shareholder structure [18] - Sichuan Medical received a notice from the Hangzhou Public Security Bureau regarding evidence collection related to a fraud investigation, highlighting ongoing legal scrutiny [20]

Core Viewpoint - The National Healthcare Security Administration (NHSA) has issued a temporary measure to manage disease-based payment systems, aiming to enhance the standardization of medical insurance payments across all regions in China [1][2]. Group 1: Payment Reform - The traditional payment method in China was fee-for-service, which often led to excessive medical practices such as over-prescribing and unnecessary tests [2]. - Since 2019, the NHSA has been promoting a "disease-based payment" reform, where payments are bundled based on historical data and patient conditions, shifting the focus from quantity of services to cost control [2][4]. - As of the end of 2024, over 90% of hospital discharges will be covered under the disease-based payment system [5]. Group 2: Impact on Medical Institutions - The reform has led to more standardized medical practices, reduced time and costs, and shorter average hospital stays [4]. - Medical institutions can apply for special cases for patients with long hospital stays or high resource consumption, allowing for project-based payments if necessary [4][5]. - Nearly 60% of tertiary public hospitals have adopted "day surgery," allowing patients to complete procedures within 24 hours, thus improving bed turnover and reducing costs [7]. Group 3: Patient Experience - The disease-based payment system reduces the financial burden on patients and encourages hospitals to control costs and standardize treatment [7]. - Patients who previously required hospitalization for simple procedures can now receive treatment as day surgeries, which are reimbursed at the same rate as inpatient care [7][9]. - In Shandong, patients can undergo simple surgeries and be discharged within 24 hours, significantly reducing hospital stay duration and costs by approximately 30% [11].

Core Viewpoint - The National Healthcare Security Administration (NHSA) has issued the "Interim Measures for Disease-Specific Payment Management," aiming to guide local governments in advancing the reform of disease-specific payment systems, particularly focusing on Diagnosis-Related Groups (DRG) and Disease-Specific Payment (DIP) methods [1][2]. Summary by Relevant Sections Reform Background - The DRG payment system was first implemented in China in 2008, with a nationwide rollout of a comprehensive DRG system starting in 2018. The DIP pilot began in 2020, marking a significant shift towards a unified national payment system [2]. - The NHSA has been actively promoting payment reform to enhance the efficiency of medical fund usage and control costs within healthcare institutions [2]. Key Features of the New Measures - The new measures emphasize three main areas: 1. Total budget management, requiring reasonable budget preparation and emphasizing the rigidity of total budget limits. 2. Standardization of grouping schemes, including clear guidelines on the formulation and adjustment of grouping schemes, which should be revised every two years. 3. Clarification of core elements and supporting measures, ensuring that key factors like weight, rate, and payment standards are well-defined [3][4]. Implementation and Adjustments - The NHSA is responsible for the formulation and adjustment of grouping schemes, while local authorities can tailor DRG subdivisions to local conditions. The grouping framework includes major diagnostic categories, core groups, and detailed subdivisions [3][4]. - Adjustments to the DRG grouping scheme will focus on maintaining stability in major diagnostic categories while allowing for changes in core and detailed groups, with a two-year adjustment cycle [4]. Transparency and Support Mechanisms - The new measures aim to enhance transparency in total budget management and provide clearer technical standards for grouping and adjustments, addressing concerns from healthcare institutions [5]. - The NHSA has also introduced supporting mechanisms, including prepayment of medical funds to qualifying institutions, which has exceeded 1.7 trillion yuan as of July 2024, and reduced settlement cycles for medical institutions [6]. Training and Capacity Building - The NHSA emphasizes the need for local healthcare departments to improve policies and supporting mechanisms, monitor reform effectiveness, and provide training for staff involved in the implementation of disease-specific payment systems [7].

Core Insights - The reform of medical insurance payment methods in China has achieved initial success, with a focus on sustainable funds, improved medical quality, and benefits for the public [2][3] - The current payment methods include Diagnosis-Related Group (DRG) and Diagnosis-Intervention Package (DIP), with 191 and 200 regions implementing these respectively, achieving 95% disease coverage and 80% fund coverage [2][3] Group 1: Reform Achievements - As of now, 24 provinces have implemented real-time settlement of medical insurance funds, covering 246,700 designated medical institutions and disbursing 165.7 billion yuan, alleviating hospital operational pressure [3][6] - The prepayment system for medical insurance funds has been effectively implemented, with a total prepayment scale of 72.3 billion yuan in the first quarter of 2025, helping public hospitals reduce financial burdens [3][6] Group 2: Challenges and Future Directions - The reform faces challenges such as the contradiction between rising medical costs and payment management, the need for quality improvement, and insufficient collaboration among stakeholders [2][3] - Future efforts will focus on building a diversified payment system and continuing to deepen the medical insurance payment reform [3][8] Group 3: Practical Insights from Experts - Experts suggest that hospitals should establish a refined operational management system centered on disease categories, integrating payment methods into daily operations to enhance management efficiency [5][6] - The Shanghai model emphasizes a flexible fee rate system and the establishment of a monitoring platform to support comprehensive management and ensure mutual benefits for medical institutions, insured patients, and the medical insurance fund [7][8]